Javelin and Myriad terminate merger pact

Javelin Pharmaceuticals and Myriad Pharmaceuticals have officially terminated their merger pact, clearing the way for Javelin to accept Hospira's $141 million buyout offer. Hospira's offer was considerably higher than Myriad's $90 million purchase price, and it included $4.4 million to cover the termination fee. Javelin submitted an NDA for its postoperative pain therapy Dyloject last December....

Javelin jilts Myriad in favor of Hospira’s $141M takeover offer

Javelin Pharmaceuticals is dumping Myriad Pharmaceuticals and its $81 million takeover deal in exchange for a much, much better deal from Hospira. Javelin shares skyrocketed 63 percent this morning after it announced that Hospira will pay $141 million for the company. Hospira not only offered $2.20 a share for Javelin--which is awaiting final word from the FDA on its application for the pain therapy Dyloject--but sweetened the deal with financing and an offer to cover a $4.4 million...